Equity Profile

KOD

Kodiak Sciences Inc.

Health CareBiotechnology$2.5B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing treatments for eye diseases....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its expenses relative to its revenues.

$-0.92

Revenue

While no revenue is expected this quarter, any commentary on future revenue potential will be closely watched by investors.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

KOD Q2-2026 Earnings Preview

Context

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing treatments for eye diseases. Operating in the health care sector, it plays a crucial role in addressing unmet medical needs in vision care, which is increasingly important as the global population ages.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

-0.51%

Last Quarter Recap

In Q1-2026, Kodiak reported an EPS of $-0.94, slightly missing the estimate of $-0.93. The stock reacted negatively, declining by 4.82% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect another challenging quarter for Kodiak, with a consensus EPS loss of $-0.92. Investors are particularly focused on any signs of progress in product development and future revenue prospects.

Bull Case

If Kodiak can demonstrate advancements in its pipeline or provide positive updates on clinical trials, it could lead to increased investor confidence and a potential stock price rebound.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides disappointing updates on its product pipeline, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$-0.92

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its expenses relative to its revenues.

Revenue

$0M

While no revenue is expected this quarter, any commentary on future revenue potential will be closely watched by investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can Kodiak provide on its product pipeline and potential revenue generation?

Investors will be looking for any signs of progress that could indicate future profitability, especially given the lack of revenue this quarter.

How does management plan to address the ongoing losses and improve EPS moving forward?

Understanding the company's strategy for managing expenses and achieving profitability is crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Kodiak's pipeline to yield positive results sooner than expected, especially given recent advancements in clinical trials.

Supporting Evidence

The options market is pricing in a 39.1% move, suggesting traders anticipate significant volatility, which may not align with consensus expectations.

Kodiak has previously shown the ability to surprise on the upside despite recent losses, indicating potential for a turnaround.

Key Risk

If the company provides a clear path to profitability or positive updates on its pipeline, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Kodiak can turn its clinical advancements into financial results, with the consensus leaning towards continued losses.

Bull Confirmed If

A narrower EPS loss of $-0.80 or better could signal improved operational efficiency and investor sentiment.

Bear Confirmed If

An EPS loss greater than $-1.04 would confirm ongoing struggles and could lead to a significant sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±39.1%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect high volatility around the earnings report.

Options are pricing ±39.1% while KOD has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

60.4%

Calls (22K)P/C Ratio: 0.43Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kodiak beats expectations with an EPS of $-0.80 or better, history suggests a potential stock increase of around 1.55% on the following day.

In-Line / Cautious

If results come in around the consensus, the stock may experience muted movement as investors await further guidance.

Miss

Should the company report a larger loss than expected, history suggests a potential decline of about 0.11% the following day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial progress and timelines for product launches.
2Management's strategy for reducing operational costs and improving EPS.
3Insights into potential partnerships or collaborations that could enhance revenue.
4Comments on market demand for their treatments and competitive positioning.
5Future guidance on expected revenue streams and timelines.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing treatments for eye diseases....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its expenses relative to its revenues.

$-0.92

Revenue

While no revenue is expected this quarter, any commentary on future revenue potential will be closely watched by investors.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

KOD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

-0.51%

Last Quarter Recap

In Q1-2026, Kodiak reported an EPS of $-0.94, slightly missing the estimate of $-0.93. The stock reacted negatively, declining by 4.82% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Kodiak can demonstrate advancements in its pipeline or provide positive updates on clinical trials, it could lead to increased investor confidence and a potential stock price rebound.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides disappointing updates on its product pipeline, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$-0.92

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its expenses relative to its revenues.

Revenue

$0M

While no revenue is expected this quarter, any commentary on future revenue potential will be closely watched by investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can Kodiak provide on its product pipeline and potential revenue generation?

Investors will be looking for any signs of progress that could indicate future profitability, especially given the lack of revenue this quarter.

How does management plan to address the ongoing losses and improve EPS moving forward?

Understanding the company's strategy for managing expenses and achieving profitability is crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Kodiak's pipeline to yield positive results sooner than expected, especially given recent advancements in clinical trials.

Supporting Evidence

The options market is pricing in a 39.1% move, suggesting traders anticipate significant volatility, which may not align with consensus expectations.

Kodiak has previously shown the ability to surprise on the upside despite recent losses, indicating potential for a turnaround.

Key Risk

If the company provides a clear path to profitability or positive updates on its pipeline, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Kodiak can turn its clinical advancements into financial results, with the consensus leaning towards continued losses.

Bull Confirmed If

A narrower EPS loss of $-0.80 or better could signal improved operational efficiency and investor sentiment.

Bear Confirmed If

An EPS loss greater than $-1.04 would confirm ongoing struggles and could lead to a significant sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±39.1%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect high volatility around the earnings report.

Options are pricing ±39.1% while KOD has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

60.4%

Calls (22K)P/C Ratio: 0.43Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kodiak beats expectations with an EPS of $-0.80 or better, history suggests a potential stock increase of around 1.55% on the following day.

In-Line / Cautious

If results come in around the consensus, the stock may experience muted movement as investors await further guidance.

Miss

Should the company report a larger loss than expected, history suggests a potential decline of about 0.11% the following day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial progress and timelines for product launches.
2Management's strategy for reducing operational costs and improving EPS.
3Insights into potential partnerships or collaborations that could enhance revenue.
4Comments on market demand for their treatments and competitive positioning.
5Future guidance on expected revenue streams and timelines.